# To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome

> **NCT06849973** · PHASE2,PHASE3 · COMPLETED · sponsor: **Biomed Industries, Inc.** · enrollment: 187 (actual)

## Conditions studied

- Rett Syndrome

## Interventions

- **DRUG:** Drug: Bionetide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06849973
- **Lead sponsor:** Biomed Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-15
- **Primary completion:** 2024-11-22
- **Final completion:** 2025-01-28
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06849973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06849973, "To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06849973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*